Reproduction permitted for personal use only. For reprints and reprint permission, contact firstname.lastname@example.org.
, which provides diverse products for the life sciences, announced an agreement with German firm Amaxa
. The two firms plan to develop applications for monitoring signals between cells that are hard to reach using other techniques, such as stem cells, cancer cells and primary cells.
"The combination of Promega and Amaxa technologies will enable researchers to obtain much more significant results with physiologically relevant cells rather than more artificial cell lines, Rainer Christine, co-founder and CEO of Amaxa, said in a press release.